Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL2333397 | 0.84 | KMT2A (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1520599 | 0.76 | MEN1 (0.65) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL11033030 | 0.75 | KMT2A (0.68) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL27885983 | 0.73 | TSHR (0.61) | MEN1KMT2AJAK2P2RX7TSHR | |
| Oxalic Acid SCHEMBL3470130 | 0.72 | KMT2A (0.63) | MEN1KMT2AALDH1A1HPGDJAK2 | |
| SCHEMBL3470125 | 0.72 | KMT2A (0.63) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL3470686 | 0.72 | MEN1 (0.63) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4384455 | 0.72 | TAS1R3 (0.60) | MEN1KMT2AALDH1A1MAPTJAK2 | |
| SCHEMBL9664793 | 0.72 | P2RX7 (0.59) | MEN1KMT2AJAK2P2RX7TSHR | |
| SCHEMBL4143751 | 0.72 | TAS1R3 (0.60) | MEN1KMT2AALDH1A1HPGDJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8518940-B2 | FP-pocket-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | MEN1 3807/4885KMT2A 2921/4885ALDH1A1 3360/4885 |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | TERF2IP, TERF2, TERT | MEN1 2732/4885KMT2A 2483/4885ALDH1A1 4190/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | MEN1 3807/4885KMT2A 2921/4885ALDH1A1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.